EMAIL THIS PAGE TO A FRIEND

British journal of pharmacology

Impaired neurogenesis by HIV-1-Gp120 is rescued by genetic deletion of fatty acid amide hydrolase enzyme.


PMID 24571443

Abstract

The HIV-envelope glycoprotein Gp120 is involved in neuronal injury and is associated with neuro-AIDS pathogenesis in the brain. Endocannabinoids are important lipid ligands in the CNS regulating neural functions, and their degeneration is controlled by hydrolysing enzymes such as the fatty acid amide hydrolase (FAAH). Here, we examined whether in vivo genetic deletion of Faah gene prevents HIV-1 Gp120-mediated effects on neurogenesis. We generated new GFAP/Gp120 transgenic (Tg) mice that have genetic deletion of Faah gene by mating glial fribillary acidic protein (GFAP)/Gp120 Tg mice with Faah-/- mice. Neurogenesis and cell death were assessed by immunocytochemical analysis. Endocannabinoid levels in the brain of the double GFAP/Gp120//Faah-/- mice were similar to those observed in Faah-/- mice. However, unlike the impaired neurogenesis observed in GFAP/Gp120 Tg mice and Faah-/- mice, these GFAP/Gp120//Faah-/ mice showed significantly improved neurogenesis in the hippocampus, indicated by a significant increase in neuroblasts and neuronal cells, an increase in BrdU(+) cells and doublecortin positive cells (DCX(+) ), and an increase in the number of PCNA. Furthermore, a significant decrease in astrogliosis and gliogenesis was observed in GFAP/Gp120//Faah-/-mice and neurogenesis was stimulated by neural progenitor cells (NPCs) and/or the newly formed NPC niches characterized by increased COX-2 expression and elevated levels of PGE2 . In vivo genetic ablation of Faah, resulted in enhanced neurogenesis through modulation of the newly generated NPC niches in GFAP/Gp120//Faah-/- mice. This suggests a novel approach of using FAAH inhibitors to enhance neurogenesis in HIV-1 infected brain.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

AV41333
Anti-DCX (AB1) antibody produced in rabbit, affinity isolated antibody
AV41332
Anti-DCX (AB2) antibody produced in rabbit, affinity isolated antibody
SAB2502091
Anti-Dcx antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2501666
Anti-DCX antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1405701
Anti-DCX antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
D9818
Anti-Doublecortin (C-terminal) antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
D9943
Anti-Doublecortin (N-terminal) antibody produced in rabbit, ~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution
D9693
Anti-Doublecortin antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
SAB4300697
Anti-Doublecortin antibody produced in rabbit, affinity isolated antibody
SAB4500628
Anti-Doublecortin antibody produced in rabbit, affinity isolated antibody
SAB4500629
Anti-Doublecortin, C-Terminal antibody produced in rabbit, affinity isolated antibody
HPA007425
Anti-FAAH antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
WH0001641M1
Monoclonal Anti-DCX antibody produced in mouse, clone 1G12, purified immunoglobulin, buffered aqueous solution
SAB1403727 Monoclonal Anti-DCX antibody produced in mouse, clone 3B7, purified immunoglobulin, buffered aqueous solution
WH0002166M7
Monoclonal Anti-FAAH antibody produced in mouse, clone 4H8, purified immunoglobulin, buffered aqueous solution
SAB1403800
Monoclonal Anti-FAAH, (C-terminal) antibody produced in mouse, clone 2G8, purified immunoglobulin, buffered aqueous solution